Preclinical and Clinical Studies
ANTICANCER RESEARCH 24: 2783-2840 (2004) Review Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies BHARAT B. AGGARWAL1, ANJANA BHARDWAJ1, RISHI S. AGGARWAL1, NAVINDRA P. SEERAM2, SHISHIR SHISHODIA1 and YASUNARI TAKADA1 1Cytokine Research Laboratory, Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030; 2UCLA Center for Human Nutrition, David Geffen School of Medicine, 900 Veteran Avenue, Los Angeles, CA 90095-1742, U.S.A. Abstract. Resveratrol, trans-3,5,4'-trihydroxystilbene, was first and cervical carcinoma. The growth-inhibitory effects of isolated in 1940 as a constituent of the roots of white hellebore resveratrol are mediated through cell-cycle arrest; up- (Veratrum grandiflorum O. Loes), but has since been found regulation of p21Cip1/WAF1, p53 and Bax; down-regulation of in various plants, including grapes, berries and peanuts. survivin, cyclin D1, cyclin E, Bcl-2, Bcl-xL and cIAPs; and Besides cardioprotective effects, resveratrol exhibits anticancer activation of caspases. Resveratrol has been shown to suppress properties, as suggested by its ability to suppress proliferation the activation of several transcription factors, including NF- of a wide variety of tumor cells, including lymphoid and Î B, AP-1 and Egr-1; to inhibit protein kinases including IÎ B· myeloid cancers; multiple myeloma; cancers of the breast, kinase, JNK, MAPK, Akt, PKC, PKD and casein kinase II; prostate, stomach, colon, pancreas, and thyroid; melanoma; and to down-regulate products of genes such as COX-2, head and neck squamous cell carcinoma; ovarian carcinoma; 5-LOX, VEGF, IL-1, IL-6, IL-8, AR and PSA.
[Show full text]